Alzheimers Disease Diagnostics Market, Report By Type (Early-Onset Alzheimers Disease and Late-Onset Alzheimers Disease), By Diagnostic Technique, By End User, By Country, and By Region Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032
|
Report ID
AV4692
|
Published Date
February 2026
|
Pages
382
|
Industry
Healthcare
|
|
|
Base Year
2025
|
Historical Data
2019-2024
|
Delivery Timeline
24 Hour
|
REPORT HIGHLIGHT
The Alzheimer’s disease Diagnostics Market size was valued at US$ 9,2190.10 Million in 2024, expanding at a CAGR of 11.19% from 2025 to 2032.
The global Alzheimer’s disease diagnostics market is experiencing steady growth, driven by the increasing prevalence of neurodegenerative disorders, a rapidly ageing population, and heightened awareness of the importance of early diagnosis. Worldwide, more than 57 million people live with dementia—including Alzheimer’s disease—with nearly 10 million new cases diagnosed each year, and these numbers are projected to rise significantly as the global population ages. Governments around the world are responding with expanded public health initiatives and increased funding allocations: many national strategies now prioritize early detection and improved diagnostic infrastructure to reduce disease burden and long-term care costs. Advances in diagnostic technologies—including biomarker-based testing, neuroimaging, and blood-based assays—are significantly enhancing detection accuracy and enabling earlier clinical intervention. In addition, supportive government policies, rising research funding, and improved access to diagnostic services are accelerating market expansion across both developed and emerging economies.
Alzheimer’s Disease Diagnostics Market- Market Dynamics
Impact of Increasing Alzheimer’s Disease Prevalence and Global Population Ageing
The growing global geriatric population and the increasing incidence of Alzheimer’s disease are key factors driving demand for advanced diagnostic solutions. Early and accurate diagnosis plays a critical role in effective disease management, timely treatment planning, and improving overall patient quality of life. For example, in January 2025, the European Brain Council reported that nearly 7 million people across Europe were living with Alzheimer’s disease; this figure is projected to double to approximately 14 million by 2030 due to the rapidly ageing population, underscoring the escalating public health burden. Advancements in diagnostic technologies—including biomarker-based assays and non-invasive neuroimaging techniques—along with growing awareness among healthcare professionals, are accelerating the adoption of Alzheimer’s disease diagnostics. Meanwhile, sustained research and development investments by diagnostic companies are strengthening product pipelines and expanding diagnostic capabilities worldwide.
Alzheimer’s disease Diagnostics Market- Segmentation Analysis:
The Global Alzheimer’s Disease Diagnostics Market is segmented on the basis of Type, Diagnostic Technique, End User, and Region.
Market by Type – Early-Onset vs. Late-Onset Alzheimer’s Disease:
The Alzheimer’s disease diagnostics market is segmented by type into Early-Onset Alzheimer’s Disease (EOAD) and Late-Onset Alzheimer’s Disease (LOAD). Late-onset Alzheimer’s disease holds a dominant market share, primarily due to its far greater prevalence in the global population aged 65 and above. LOAD accounts for more than 90–95 % of all Alzheimer’s cases worldwide, whereas early-onset forms represent a relatively small fraction (around 5–10 %) of the total disease burden. The rising proportion of older adults—driven by increasing life expectancy and demographic ageing in countries such as China and across Europe—has significantly expanded the pool of individuals at risk for late-onset Alzheimer’s disease, reinforcing this segment’s market leadership. Government health agencies in multiple countries have highlighted Alzheimer’s disease as a major public health challenge linked to ageing populations, with national strategies increasingly emphasizing early detection and care pathways for older adults.
Market by Diagnostic Technique – Neuroimaging, Biomarkers, Genetic & Cognitive Tests:
In the diagnostic techniques segment, neuroimaging and biomarker-based diagnostics collectively command a substantial share of the Alzheimer’s disease diagnostics market. Techniques such as positron emission tomography (PET), magnetic resonance imaging (MRI), and cerebrospinal fluid or blood-based biomarkers have become central to clinical practice because they offer high diagnostic accuracy and can detect disease-related changes earlier in the disease course than traditional methods. This trend is supported by government and international health bodies that increasingly recommend advanced imaging and biomarker tests to support clinical diagnosis, integrate into clinical trials, and enable more precise patient stratification. For example, national health diagnostic guidelines in high-income countries often mandate the use of validated biomarkers for Alzheimer’s diagnosis, and agencies such as the World Health Organization are actively promoting blood-based biomarker test development to improve accessibility, especially in settings with limited imaging infrastructure. Cognitive and genetic tests continue to play a complementary role, particularly in early assessments and risk evaluation, but the integration of high-resolution imaging and novel biomarkers is driving the highest growth within this market segment.
Market by End User – Hospitals & Clinics, Diagnostic Laboratories, Research Institutes:
By end user, hospitals and diagnostic laboratories dominate the Alzheimer’s disease diagnostics market due to their ability to provide comprehensive services, advanced infrastructure, and multidisciplinary clinical expertise. Hospitals, with established neurology departments and integrated diagnostic units, account for a large portion of diagnostic revenue, reflecting the high patient inflow and referral systems that facilitate early and accurate diagnosis. Diagnostic laboratories are also major contributors, offering specialized biomarker analyses and genetic testing that are essential for confirming clinical suspicions and supporting precision medicine approaches. Many governments have strengthened hospital-based screening initiatives and reimbursed diagnostic procedures for ageing populations, further solidifying these settings’ leadership in the market. Research institutes and academic centers, while smaller in share, are key drivers of innovation, often collaborating with public health agencies and receiving government grants to advance new diagnostic tools and clinical validation studies.
Alzheimer’s Disease Diagnostics Market- Geographical Insights
North America holds the leading position in the Alzheimer’s disease diagnostics market, accounting for nearly half of global market share in 2025 due to its advanced healthcare infrastructure, strong public awareness, and rapid uptake of cutting-edge diagnostic technologies. These advantages support early detection and timely intervention, which are essential for effective disease management. In the United States alone, an estimated 6.7 million Americans aged 65 and older are living with Alzheimer’s dementia, a number expected to nearly double by 2060, reinforcing the need for robust diagnostic services and policy support.
Europe follows closely, supported by well-established research institutions and proactive government healthcare policies that promote investment in early detection and new diagnostic methodologies. Several European countries have national dementia plans that prioritize early screening and memory clinic networks, reflecting wider public health efforts to manage the disease burden. Across the globe, over 55 million people currently live with dementia, a figure projected to rise substantially as populations age, further motivating regional diagnostic investments.
In the Asia-Pacific region, rapid market growth is anticipated due to a significantly ageing population, expanding healthcare access, and increasing public and private investments in diagnostic infrastructure—especially in major markets such as China, Japan, and India. Governments in these countries are increasingly prioritizing cognitive health, with initiatives to broaden access to diagnostic tools and integrate Alzheimer’s screening into routine care settings. Meanwhile, Latin America and the Middle East & Africa are experiencing gradual growth as public awareness improves and diagnostic capabilities expand, contributing to better patient management and outcomes in these regions.
Alzheimer’s Disease Diagnostics Market- Country Insights
The United States holds a dominant position in the Alzheimer’s disease diagnostics market, driven by the high utilization of diagnostic tests, well-established reimbursement frameworks that support patient access to advanced technologies, and the presence of leading diagnostic companies actively driving innovation. Together, these factors create a favorable environment for the rapid development and adoption of novel diagnostic methods.
In Europe, key markets such as Germany, the United Kingdom, and France play a significant role, supported by advanced healthcare systems that emphasize high standards of care and sustained research efforts aimed at improving diagnostic accuracy and developing innovative testing solutions.
Meanwhile, China and India are emerging as high-growth markets, fueled by large and growing patient populations, expanding diagnostic networks, and improving access to essential healthcare services. Both countries are increasingly prioritizing early disease detection and preventive healthcare strategies, aligning with global trends toward proactive disease management. Collectively, these factors position China and India for accelerated growth in the Alzheimer’s disease diagnostics landscape, ultimately contributing to improved patient outcomes. In India, an estimated 8.8 million adults aged 60+ are living with dementia, with prevalence rising as life expectancy increases, prompting greater emphasis on early screening and healthcare infrastructure development.
Alzheimer’s disease Diagnostics Market- Competitive Landscape:
The Alzheimer’s disease diagnostics market is moderately competitive, with leading players focusing on technological innovation, biomarker discovery, and strategic collaborations to strengthen their market positions. Companies are increasingly investing in advanced blood-based diagnostics, neuroimaging solutions, and AI-enabled tools to improve early detection and enhance clinical outcomes. Ongoing clinical trials for novel biomarkers and investigational diagnostic technologies continue to drive innovation and support overall market growth. For example, in August 2025, BGI Genomics developed an in-house blood-based diagnostic test for Alzheimer’s disease and other cognitive disorders, following national regulatory approval in China received in April 2024. The test analyzes five key blood-based biomarkers—including specific tau and amyloid protein variants, along with additional neuro-related indicators—providing clinicians with a more comprehensive assessment of underlying brain pathology.
Major industry leaders such as Abbott Laboratories, Roche Diagnostics, and Siemens Healthineers leverage their extensive research and development capabilities to advance cutting-edge diagnostic technologies. GE HealthCare and Fujirebio specialize in advanced neuroimaging solutions and biomarker assays, further enhancing diagnostic precision. Meanwhile, Biogen and Quanterix focus on innovative therapeutic and diagnostic approaches to address the complexities of Alzheimer’s disease. Companies including C2N Diagnostics, Thermo Fisher Scientific, and Danaher Corporation also play a significant role by offering specialized tools and technologies that support early and accurate diagnosis. Collectively, these players shape a dynamic and innovation-driven landscape aimed at improving the understanding and management of Alzheimer’s disease through enhanced diagnostic capabilities.
Recent Developments:
- May 16, 2025: The U.S. Food and Drug Administration (FDA) cleared the first in vitro blood test to aid in the diagnosis of Alzheimer’s disease. Developed by Fujirebio Diagnostics, Inc., the Lumipulse G pTau217 / β-Amyloid 1-42 Plasma Ratio is designed to detect amyloid plaques in adults aged 55 years and older who present with symptoms of cognitive impairment.
- August 2025: C2N Diagnostics, LLC announced a major global expansion of its PrecivityAD2 blood test, extending availability to additional healthcare providers across Asia, Europe, Latin America, and the Middle East. This expansion aims to increase access to high-precision Alzheimer’s diagnostics, particularly in regions with limited neuroimaging infrastructure.
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL ALZHEIMER’S DISEASE DIAGNOSTICS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS
- Abbott Laboratories
- Roche Diagnostics
- Siemens Healthineers
- GE HealthCare
- Fujirebio
- Biogen
- Quanterix
- C2N Diagnostics
- Thermo Fisher Scientific
- Danaher Corporation
- Others
GLOBAL ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY TYPE - MARKET ANALYSIS, 2019 - 2032
- Early-Onset Alzheimer’s Disease
- Late-Onset Alzheimer’s Disease
- Others
GLOBAL ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY DIAGNOSTIC TECHNIQUE ANALYSIS, 2019 - 2032
- Neuroimaging
- Biomarker Tests
- Genetic Testing
- Cognitive Tests
- Others
GLOBAL ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY END USER - MARKET ANALYSIS, 2019 - 2032
- Hospitals & Clinics
- Diagnostic Laboratories
- Research Institutes
- Others
GLOBAL ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032
North America
- U.S.
- Canada
Europe
- Germany
- UK
- France
- Italy
- Spain
- The Netherlands
- Sweden
- Russia
- Poland
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Australia
- Indonesia
- Thailand
- Philippines
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of LATAM
The Middle East and Africa
- Saudi Arabia
- UAE
- Israel
- Turkey
- Algeria
- Egypt
- Rest of MEA
TABLE OF CONTENT
1. Alzheimer’s Disease Diagnostics Market Overview
1.1. Study Scope
1.2. Market Estimation Years
2. Executive Summary
2.1. Market Snippet
2.1.1. Alzheimer’s Disease Diagnostics Market Snippet by Type
2.1.2. Alzheimer’s Disease Diagnostics Market Snippet by Diagnostic Technique
2.1.3. Alzheimer’s Disease Diagnostics Market Snippet by End User
2.1.4. Alzheimer’s Disease Diagnostics Market Snippet by Country
2.1.5. Alzheimer’s Disease Diagnostics Market Snippet by Region
2.2. Competitive Insights
3. Alzheimer’s Disease Diagnostics Key Market Trends
3.1. Alzheimer’s Disease Diagnostics Market Drivers
3.1.1. Impact Analysis of Market Drivers
3.2. Alzheimer’s Disease Diagnostics Market Restraints
3.2.1. Impact Analysis of Market Restraints
3.3. Alzheimer’s Disease Diagnostics Market Opportunities
3.4. Alzheimer’s Disease Diagnostics Market Future Trends
4. Alzheimer’s Disease Diagnostics Industry Study
4.1. PEST Analysis
4.2. Porter’s Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis
5. Alzheimer’s Disease Diagnostics Market: Impact of Escalating Geopolitical Tensions
5.1. Impact of COVID-19 Pandemic
5.2. Impact of Russia-Ukraine War
5.3. Impact of Middle East Conflicts
6. Alzheimer’s Disease Diagnostics Market Landscape
6.1. Alzheimer’s Disease Diagnostics Market Share Analysis, 2024
6.2. Breakdown Data, by Key Manufacturer
6.2.1. Established Players’ Analysis
6.2.2. Emerging Players’ Analysis
7. Alzheimer’s Disease Diagnostics Market – By Type
7.1. Overview
7.1.1. Segment Share Analysis, By Type, 2024&2032 (%)
7.1.2. Early-Onset Alzheimer’s Disease
7.1.3. Late-Onset Alzheimer’s Disease
7.1.4. Others
8. Alzheimer’s Disease Diagnostics Market – By Diagnostic Technique
8.1. Overview
8.1.1. Segment Share Analysis, By Diagnostic Technique, 2024&2032 (%)
8.1.2. Neuroimaging
8.1.3. Biomarker Tests
8.1.4. Genetic Testing
8.1.5. Cognitive Tests
8.1.6. Others
9. Alzheimer’s Disease Diagnostics Market – By End User
9.1. Overview
9.1.1. Segment Share Analysis, By End User, 2024&2032 (%)
9.1.2. Hospitals & Clinics
9.1.3. Diagnostic Laboratories
9.1.4. Research Institutes
9.1.5. Others
10. Alzheimer’s Disease Diagnostics Market– By Geography
10.1. Introduction
10.1.1. Segment Share Analysis, By Geography, 2024&2032 (%)
10.2. North America
10.2.1. Overview
10.2.2. Alzheimer’s Disease Diagnostics Key Manufacturers in North America
10.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Billion)
10.2.4. North America Market Size and Forecast, By Type, 2019 - 2032 (US$ Billion)
10.2.5. North America Market Size and Forecast, By Diagnostic Technique, 2019 - 2032 (US$ Billion)
10.2.6. North America Market Size and Forecast, By End User, 2019 - 2032 (US$ Billion)
10.2.7. U.S.
10.2.7.1. Overview
10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Billion)
10.2.7.3. U.S. Market Size and Forecast, By Type, 2019 - 2032 (US$ Billion)
10.2.7.4. U.S. Market Size and Forecast, By Diagnostic Technique, 2019 - 2032 (US$ Billion)
10.2.7.5. U.S. Market Size and Forecast, By End User, 2019 - 2032 (US$ Billion)
10.2.8. Canada
10.2.8.1. Overview
10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Billion)
10.2.8.3. Canada Market Size and Forecast, By Type, 2019 - 2032 (US$ Billion)
10.2.8.4. Canada Market Size and Forecast, By Diagnostic Technique, 2019 - 2032 (US$ Billion)
10.2.8.5. Canada Market Size and Forecast, By End User, 2019 - 2032 (US$ Billion)
10.3. Europe
10.3.1. Overview
10.3.2. Alzheimer’s Disease Diagnostics Key Manufacturers in Europe
10.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Billion)
10.3.4. Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Billion)
10.3.5. Europe Market Size and Forecast, By Diagnostic Technique, 2019 - 2032 (US$ Billion)
10.3.6. Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Billion)
10.3.7. Germany
10.3.7.1. Overview
10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Billion)
10.3.7.3. Germany Market Size and Forecast, By Type, 2019 - 2032 (US$ Billion)
10.3.7.4. Germany Market Size and Forecast, By Diagnostic Technique, 2019 - 2032 (US$ Billion)
10.3.7.5. Germany Market Size and Forecast, By End User, 2019 - 2032 (US$ Billion)
10.3.8. UK
10.3.8.1. Overview
10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Billion)
10.3.8.3. UK Market Size and Forecast, By Type, 2019 - 2032 (US$ Billion)
10.3.8.4. UK Market Size and Forecast, By Diagnostic Technique, 2019 - 2032 (US$ Billion)
10.3.8.5. UK Market Size and Forecast, By End User, 2019 - 2032 (US$ Billion)
10.3.9. France
10.3.9.1. Overview
10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Billion)
10.3.9.3. France Market Size and Forecast, By Type, 2019 - 2032 (US$ Billion)
10.3.9.4. France Market Size and Forecast, By Diagnostic Technique, 2019 - 2032 (US$ Billion)
10.3.9.5. France Market Size and Forecast, By End User, 2019 - 2032 (US$ Billion)
10.3.10. Italy
10.3.10.1. Overview
10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Billion)
10.3.10.3. Italy Market Size and Forecast, By Type, 2019 - 2032 (US$ Billion)
10.3.10.4. Italy Market Size and Forecast, By Diagnostic Technique, 2019 - 2032 (US$ Billion)
10.3.10.5. Italy Market Size and Forecast, By End User, 2019 - 2032 (US$ Billion)
10.3.11. Spain
10.3.11.1. Overview
10.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Billion)
10.3.11.3. Spain Market Size and Forecast, By Type, 2019 - 2032 (US$ Billion)
10.3.11.4. Spain Market Size and Forecast, By Diagnostic Technique, 2019 - 2032 (US$ Billion)
10.3.11.5. Spain Market Size and Forecast, By End User, 2019 - 2032 (US$ Billion)
10.3.12. The Netherlands
10.3.12.1. Overview
10.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Billion)
10.3.12.3. The Netherlands Market Size and Forecast, By Type, 2019 - 2032 (US$ Billion)
10.3.12.4. The Netherlands Market Size and Forecast, By Diagnostic Technique, 2019 - 2032 (US$ Billion)
10.3.12.5. The Netherlands Market Size and Forecast, By End User, 2019 - 2032 (US$ Billion)
10.3.13. Sweden
10.3.13.1. Overview
10.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Billion)
10.3.13.3. Sweden Market Size and Forecast, By Type, 2019 - 2032 (US$ Billion)
10.3.13.4. Sweden Market Size and Forecast, By Diagnostic Technique, 2019 - 2032 (US$ Billion)
10.3.13.5. Sweden Market Size and Forecast, By End User, 2019 - 2032 (US$ Billion)
10.3.14. Russia
10.3.14.1. Overview
10.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Billion)
10.3.14.3. Russia Market Size and Forecast, By Type, 2019 - 2032 (US$ Billion)
10.3.14.4. Russia Market Size and Forecast, By Diagnostic Technique, 2019 - 2032 (US$ Billion)
10.3.14.5. Russia Market Size and Forecast, By End User, 2019 - 2032 (US$ Billion)
10.3.15. Poland
10.3.15.1. Overview
10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Billion)
10.3.15.3. Poland Market Size and Forecast, By Type, 2019 - 2032 (US$ Billion)
10.3.15.4. Poland Market Size and Forecast, By Diagnostic Technique, 2019 - 2032 (US$ Billion)
10.3.15.5. Poland Market Size and Forecast, By End User, 2019 - 2032 (US$ Billion)
10.3.16. Rest of Europe
10.3.16.1. Overview
10.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Billion)
10.3.16.3. Rest of the Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Billion)
10.3.16.4. Rest of the Europe Market Size and Forecast, By Diagnostic Technique, 2019 - 2032 (US$ Billion)
10.3.16.5. Rest of the Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Billion)
10.4. Asia Pacific (APAC)
10.4.1. Overview
10.4.2. Alzheimer’s Disease Diagnostics Key Manufacturers in Asia Pacific
10.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Billion)
10.4.4. APAC Market Size and Forecast, By Type, 2019 - 2032 (US$ Billion)
10.4.5. APAC Market Size and Forecast, By Diagnostic Technique, 2019 - 2032 (US$ Billion)
10.4.6. APAC Market Size and Forecast, By End User, 2019 - 2032 (US$ Billion)
10.4.7. China
10.4.7.1. Overview
10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Billion)
10.4.7.3. China Market Size and Forecast, By Type, 2019 - 2032 (US$ Billion)
10.4.7.4. China Market Size and Forecast, By Diagnostic Technique, 2019 - 2032 (US$ Billion)
10.4.7.5. China Market Size and Forecast, By End User, 2019 - 2032 (US$ Billion)
10.4.8. India
10.4.8.1. Overview
10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Billion)
10.4.8.3. India Market Size and Forecast, By Type, 2019 - 2032 (US$ Billion)
10.4.8.4. India Market Size and Forecast, By Diagnostic Technique, 2019 - 2032 (US$ Billion)
10.4.8.5. India Market Size and Forecast, By End User, 2019 - 2032 (US$ Billion)
10.4.9. Japan
10.4.9.1. Overview
10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Billion)
10.4.9.3. Japan Market Size and Forecast, By Type, 2019 - 2032 (US$ Billion)
10.4.9.4. Japan Market Size and Forecast, By Diagnostic Technique, 2019 - 2032 (US$ Billion)
10.4.9.5. Japan Market Size and Forecast, By End User, 2019 - 2032 (US$ Billion)
10.4.10. South Korea
10.4.10.1. Overview
10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Billion)
10.4.10.3. South Korea Market Size and Forecast, By Type, 2019 - 2032 (US$ Billion)
10.4.10.4. South Korea Market Size and Forecast, By Diagnostic Technique, 2019 - 2032 (US$ Billion)
10.4.10.5. South Korea Market Size and Forecast, By End User, 2019 - 2032 (US$ Billion)
10.4.11. Australia
10.4.11.1. Overview
10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Billion)
10.4.11.3. Australia Market Size and Forecast, By Type, 2019 - 2032 (US$ Billion)
10.4.11.4. Australia Market Size and Forecast, By Diagnostic Technique, 2019 - 2032 (US$ Billion)
10.4.11.5. Australia Market Size and Forecast, By End User, 2019 - 2032 (US$ Billion)
10.4.12. Indonesia
10.4.12.1. Overview
10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Billion)
10.4.12.3. Indonesia Market Size and Forecast, By Type, 2019 - 2032 (US$ Billion)
10.4.12.4. Indonesia Market Size and Forecast, By Diagnostic Technique, 2019 - 2032 (US$ Billion)
10.4.12.5. Indonesia Market Size and Forecast, By End User, 2019 - 2032 (US$ Billion)
10.4.13. Thailand
10.4.13.1. Overview
10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Billion)
10.4.13.3. Thailand Market Size and Forecast, By Type, 2019 - 2032 (US$ Billion)
10.4.13.4. Thailand Market Size and Forecast, By Diagnostic Technique, 2019 - 2032 (US$ Billion)
10.4.13.5. Thailand Market Size and Forecast, By End User, 2019 - 2032 (US$ Billion)
10.4.14. Philippines
10.4.14.1. Overview
10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Billion)
10.4.14.3. PhilippinesMarket Size and Forecast, By Type, 2019 - 2032 (US$ Billion)
10.4.14.4. Philippines Market Size and Forecast, By Diagnostic Technique, 2019 - 2032 (US$ Billion)
10.4.14.5. Philippines Market Size and Forecast, By End User, 2019 - 2032 (US$ Billion)
10.4.15. Rest of APAC
10.4.15.1. Overview
10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Billion)
10.4.15.3. Rest of APAC Market Size and Forecast, By Type, 2019 - 2032 (US$ Billion)
10.4.15.4. Rest of APAC Market Size and Forecast, By Diagnostic Technique, 2019 - 2032 (US$ Billion)
10.4.15.5. Rest of APAC Market Size and Forecast, By End User, 2019 - 2032 (US$ Billion)
10.5. Latin America (LATAM)
10.5.1. Overview
10.5.2. Alzheimer’s Disease Diagnostics Key Manufacturers in Latin America
10.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Billion)
10.5.4. LATAM Market Size and Forecast, By Type, 2019 - 2032 (US$ Billion)
10.5.5. LATAM Market Size and Forecast, By Diagnostic Technique, 2019 - 2032 (US$ Billion)
10.5.6. LATAM Market Size and Forecast, By End User, 2019 - 2032 (US$ Billion)
10.5.7. Brazil
10.5.7.1. Overview
10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Billion)
10.5.7.3. Brazil Market Size and Forecast, By Type, 2019 - 2032 (US$ Billion)
10.5.7.4. Brazil Market Size and Forecast, By Diagnostic Technique, 2019 - 2032 (US$ Billion)
10.5.7.5. Brazil Market Size and Forecast, By End User, 2019 - 2032 (US$ Billion)
10.5.8. Mexico
10.5.8.1. Overview
10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Billion)
10.5.8.3. Mexico Market Size and Forecast, By Type, 2019 - 2032 (US$ Billion)
10.5.8.4. Mexico Market Size and Forecast, By Diagnostic Technique, 2019 - 2032 (US$ Billion)
10.5.8.5. Mexico Market Size and Forecast, By End User, 2019 - 2032 (US$ Billion)
10.5.9. Argentina
10.5.9.1. Overview
10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Billion)
10.5.9.3. Argentina Market Size and Forecast, By Type, 2019 - 2032 (US$ Billion)
10.5.9.4. Argentina Market Size and Forecast, By Diagnostic Technique, 2019 - 2032 (US$ Billion)
10.5.9.5. Argentina Market Size and Forecast, By End User, 2019 - 2032 (US$ Billion)
10.5.10. Colombia
10.5.10.1. Overview
10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Billion)
10.5.10.3. Colombia Market Size and Forecast, By Type, 2019 - 2032 (US$ Billion)
10.5.10.4. Colombia Market Size and Forecast, By Diagnostic Technique, 2019 - 2032 (US$ Billion)
10.5.10.5. Colombia Market Size and Forecast, By End User, 2019 - 2032 (US$ Billion)
10.5.11. Rest of LATAM
10.5.11.1. Overview
10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Billion)
10.5.11.3. Rest of LATAM Market Size and Forecast, By Type, 2019 - 2032 (US$ Billion)
10.5.11.4. Rest of LATAM Market Size and Forecast, By Diagnostic Technique, 2019 - 2032 (US$ Billion)
10.5.11.5. Rest of LATAM Market Size and Forecast, By End User, 2019 - 2032 (US$ Billion)
10.6. Middle East and Africa (MEA)
10.6.1. Overview
10.6.2. Alzheimer’s Disease DiagnosticsKey Manufacturers in Middle East and Africa
10.6.3. MEA Market Size and Forecast, By Country, 2019 - 2032 (US$ Billion)
10.6.4. MEA Market Size and Forecast, By Type, 2019 - 2032 (US$ Billion)
10.6.5. MEA Market Size and Forecast, By Diagnostic Technique, 2019 - 2032 (US$ Billion)
10.6.6. MEA Market Size and Forecast, By End User, 2019 - 2032 (US$ Billion)
10.6.7. Saudi Arabia
10.6.7.1. Overview
10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Billion)
10.6.7.3. Saudi Arabia Market Size and Forecast, By Type, 2019 - 2032 (US$ Billion)
10.6.7.4. Saudi Arabia Market Size and Forecast, By Diagnostic Technique, 2019 - 2032 (US$ Billion)
10.6.7.5. Saudi Arabia Market Size and Forecast, By End User, 2019 - 2032 (US$ Billion)
10.6.8. UAE
10.6.8.1. Overview
10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Billion)
10.6.8.3. UAE Market Size and Forecast, By Type, 2019 - 2032 (US$ Billion)
10.6.8.4. UAE Market Size and Forecast, By Diagnostic Technique, 2019 - 2032 (US$ Billion)
10.6.8.5. UAE Market Size and Forecast, By End User, 2019 - 2032 (US$ Billion)
10.6.9. Israel
10.6.9.1. Overview
10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Billion)
10.6.9.3. Israel Market Size and Forecast, By Type, 2019 - 2032 (US$ Billion)
10.6.9.4. Israel Market Size and Forecast, By Diagnostic Technique, 2019 - 2032 (US$ Billion)
10.6.9.5. Israel Market Size and Forecast, By End User, 2019 - 2032 (US$ Billion)
10.6.10. Turkey
10.6.10.1. Overview
10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Billion)
10.6.10.3. Turkey Market Size and Forecast, By Type, 2019 - 2032 (US$ Billion)
10.6.10.4. Turkey Market Size and Forecast, By Diagnostic Technique, 2019 - 2032 (US$ Billion)
10.6.10.5. Turkey Market Size and Forecast, By End User, 2019 - 2032 (US$ Billion)
10.6.11. Algeria
10.6.11.1. Overview
10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Billion)
10.6.11.3. Algeria Market Size and Forecast, By Type, 2019 - 2032 (US$ Billion)
10.6.11.4. Algeria Market Size and Forecast, By Diagnostic Technique, 2019 - 2032 (US$ Billion)
10.6.11.5. Algeria Market Size and Forecast, By End User, 2019 - 2032 (US$ Billion)
10.6.12. Egypt
10.6.12.1. Overview
10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Billion)
10.6.12.3. Egypt Market Size and Forecast, By Type, 2019 - 2032 (US$ Billion)
10.6.12.4. Egypt Market Size and Forecast, By Diagnostic Technique, 2019 - 2032 (US$ Billion)
10.6.12.5. Egypt Market Size and Forecast, By End User, 2019 - 2032 (US$ Billion)
10.6.13. Rest of MEA
10.6.13.1. Overview
10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Billion)
10.6.13.3. Rest of MEA Market Size and Forecast, By Type, 2019 - 2032 (US$ Billion)
10.6.13.4. Rest of MEA Market Size and Forecast, By Diagnostic Technique, 2019 - 2032 (US$ Billion)
10.6.13.5. Rest of MEA Market Size and Forecast, By End User, 2019 - 2032 (US$ Billion)
11. Key Vendor Analysis- Alzheimer’s Disease Diagnostics Industry
11.1. Competitive Dashboard
11.1.1. Competitive Benchmarking
11.1.2. Competitive Positioning
11.2. Company Profiles
11.2.1. Abbott Laboratories
11.2.2. Roche Diagnostics
11.2.3. Siemens Healthineers
11.2.4. GE HealthCare
11.2.5. Fujirebio
11.2.6. Biogen
11.2.7. Quanterix
11.2.8. C2N Diagnostics
11.2.9. Thermo Fisher Scientific
11.2.10. Danaher Corporation
11.2.11. Others
12. 360 Degree Analyst View
13. Appendix
13.1. Research Methodology
13.2. References
13.3. Abbreviations
13.4. Disclaimer
13.5. Contact Us
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL ALZHEIMER’S DISEASE DIAGNOSTICS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS
- Abbott Laboratories
- Roche Diagnostics
- Siemens Healthineers
- GE HealthCare
- Fujirebio
- Biogen
- Quanterix
- C2N Diagnostics
- Thermo Fisher Scientific
- Danaher Corporation
- Others
GLOBAL ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY TYPE - MARKET ANALYSIS, 2019 - 2032
- Early-Onset Alzheimer’s Disease
- Late-Onset Alzheimer’s Disease
- Others
GLOBAL ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY DIAGNOSTIC TECHNIQUE ANALYSIS, 2019 - 2032
- Neuroimaging
- Biomarker Tests
- Genetic Testing
- Cognitive Tests
- Others
GLOBAL ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY END USER - MARKET ANALYSIS, 2019 - 2032
- Hospitals & Clinics
- Diagnostic Laboratories
- Research Institutes
- Others
GLOBAL ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032
North America
- U.S.
- Canada
Europe
- Germany
- UK
- France
- Italy
- Spain
- The Netherlands
- Sweden
- Russia
- Poland
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Australia
- Indonesia
- Thailand
- Philippines
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of LATAM
The Middle East and Africa
- Saudi Arabia
- UAE
- Israel
- Turkey
- Algeria
- Egypt
- Rest of MEA
Related Reports
Credibility and Certifications
Trusted Insights, Certified Excellence! Coherent Market Insights is a certified data advisory and business consulting firm recognized by global institutes.
ISO 9001:2015
ESOMAR Corporate
GDPR Compliance
D-U-N-S Registered
BBB Accreditation
MRS
